Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family... ( Company Enrolls First Patient into SP...)

HOME >> MEDICINE >> NEWS

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials

Date:6/16/2009

Company Enrolls First Patient into SPIRIT PRIME Trial in the United States

ABBOTT PARK, Ill., June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System, currently an investigational device, for the treatment of coronary artery disease. Results from SPIRIT PRIME will be used to support the regulatory filing for XIENCE PRIME in the United States. The first patient was enrolled into the SPIRIT PRIME clinical trial at Hillcrest Medical Center in Tulsa, Okla., by Rajesh Chandwaney, M.D.

XIENCE PRIME utilizes the same well-studied drug and proven biocompatible polymer as Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. In addition, it offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. XIENCE PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. XIENCE PRIME is based upon the proven design of the MULTI-LINK(R) family of stents, which is the most widely used stent platform in the world - with more than 2 million implants worldwide. The company expects to launch XIENCE PRIME in a broad size matrix with sizes up to 38 mm in Europe later this year.

"XIENCE PRIME carries the same successful drug and polymer as the XIENCE V stent. Its stent platform and delivery balloon are designed to be highly deliverable, and as such, XIENCE PRIME has the potential to simplify procedures in challenging cases," said Marco A. Costa, M.D., Ph.D., FACC, FSCAI, professor of medicine, director of the Interventional Cardiol
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Abbott Declares 342nd Consecutive Quarterly Dividend
2. Abbott Announces Launch of Next-Generation Embolic Protection System
3. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
4. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
5. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
6. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
7. Abbott to Present at Goldman Sachs Global Healthcare Conference
8. Feeding America and Abbott Partner For Hurricane Relief
9. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
10. Abbott Announces EuroPCR 2009 Activities
11. Victory! Colombian Government Cuts Price of Abbotts Lifesaving AIDS Drug Kaletra 55%, Says AHF

Post Your Comments:

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family...( Company Enrolls First Patient into SP...),Health